Design, synthesis, and biological evaluation of novel AAK1/HDACs dual inhibitors against SARS-CoV-2 entry
- 19 November 2024
- journal article
- research article
- Published by Elsevier in Bioorganic Chemistry
- Vol. 153, 107973
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- HAT and HDAC: Enzyme with Contradictory Action in Neurodegenerative DiseasesMolecular Neurobiology, 2024
- Targeting SARS-CoV-2 entry processes: The promising potential and future of host-targeted small-molecule inhibitorsEuropean Journal of Medicinal Chemistry, 2023
- Recent histone deacetylase inhibitors in cancer therapyCancer, 2023
- Design, Synthesis and Biological Evaluation of Histone Deacetylase Inhibitors Based on Pyrrolo[2,3‐d]pyrimidine and Pyrrolo[2,3‐b]pyridine ScaffoldsChemMedChem, 2023
- Numb-associated kinases are required for SARS-CoV-2 infection and are cellular targets for antiviral strategiesAntiviral Research, 2022
- Medicinal chemistry updates of novel HDACs inhibitors (2020 to present)European Journal of Medicinal Chemistry, 2022
- Erianin inhibits the oncogenic properties of hepatocellular carcinoma via inducing DNA damage and aberrant mitosisBiochemical Pharmacology, 2020
- Dual inhibitors of histone deacetylases and other cancer-related targets: A pharmacological perspectiveBiochemical Pharmacology, 2020
- Panobinostat: A Review in Relapsed or Refractory Multiple MyelomaTargeted Oncology, 2016
- Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicityCancer Chemotherapy and Pharmacology, 2011